Details for New Drug Application (NDA): 201281
✉ Email this page to a colleague
The generic ingredient in JENTADUETO is linagliptin; metformin hydrochloride. There are nineteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the linagliptin; metformin hydrochloride profile page.
Summary for 201281
Tradename: | JENTADUETO |
Applicant: | Boehringer Ingelheim |
Ingredient: | linagliptin; metformin hydrochloride |
Patents: | 9 |
Pharmacology for NDA: 201281
Mechanism of Action | Dipeptidyl Peptidase 4 Inhibitors |
Suppliers and Packaging for NDA: 201281
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
JENTADUETO | linagliptin; metformin hydrochloride | TABLET;ORAL | 201281 | NDA | Boehringer Ingelheim Pharmaceuticals, Inc. | 0597-0146 | 0597-0146-18 | 180 TABLET, FILM COATED in 1 BOTTLE (0597-0146-18) |
JENTADUETO | linagliptin; metformin hydrochloride | TABLET;ORAL | 201281 | NDA | Boehringer Ingelheim Pharmaceuticals, Inc. | 0597-0146 | 0597-0146-60 | 60 TABLET, FILM COATED in 1 BOTTLE (0597-0146-60) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 2.5MG;500MG | ||||
Approval Date: | Jan 30, 2012 | TE: | AB | RLD: | Yes | ||||
Regulatory Exclusivity Expiration: | Dec 20, 2026 | ||||||||
Regulatory Exclusivity Use: | PEDIATRIC EXCLUSIVITY | ||||||||
Regulatory Exclusivity Expiration: | Jun 20, 2026 | ||||||||
Regulatory Exclusivity Use: | REVISIONS TO THE PEDIATRIC USE SUBSECTION OF LABELING TO INCLUDE THE RESULTS FROM CLINICAL STUDY 1218-0091, CONDUCTED TO FULFILL A PEDIATRIC WRITTEN REQUEST | ||||||||
Patent: | ⤷ Sign Up | Patent Expiration: | Oct 2, 2029 | Product Flag? | Substance Flag? | Delist Request? | Y |
Expired US Patents for NDA 201281
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Boehringer Ingelheim | JENTADUETO | linagliptin; metformin hydrochloride | TABLET;ORAL | 201281-001 | Jan 30, 2012 | ⤷ Sign Up | ⤷ Sign Up |
Boehringer Ingelheim | JENTADUETO | linagliptin; metformin hydrochloride | TABLET;ORAL | 201281-003 | Jan 30, 2012 | ⤷ Sign Up | ⤷ Sign Up |
Boehringer Ingelheim | JENTADUETO | linagliptin; metformin hydrochloride | TABLET;ORAL | 201281-002 | Jan 30, 2012 | ⤷ Sign Up | ⤷ Sign Up |
Boehringer Ingelheim | JENTADUETO | linagliptin; metformin hydrochloride | TABLET;ORAL | 201281-002 | Jan 30, 2012 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription